Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? (Q49071066)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

title

Peritumoral indoleamine 2,3-dioxygenase expression in melanoma: an early marker of resistance to immune control? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

Vibeke Kruse

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

author name string

I Chevolet

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

R Speeckaert

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

M Haspeslagh

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

M Schreuer

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

M Van Gele

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

N Van Geel

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

L Brochez

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

language of work or name

English

0 references

publication date

6 October 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Dermatology

18 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

volume

171

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

18 March 2020

page(s)

987-995

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

Prevention of allogeneic fetal rejection by tryptophan catabolism

18 March 2020

cites work

1 reference

CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase

21 January 2018

1 reference

Role of IFNγ in Allograft Tolerance Mediated by CD4+CD25+Regulatory T Cells by Induction of IDO in Endothelial Cells

21 January 2018

1 reference

Immunosuppressive networks in the tumour environment and their therapeutic relevance

21 January 2018

1 reference

Host indoleamine 2,3-dioxygenase: contribution to systemic acquired tumor tolerance.

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients.

21 January 2018

1 reference

Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells.

21 January 2018

1 reference

Inverse correlation between tumoral indoleamine 2,3-dioxygenase expression and tumor-infiltrating lymphocytes in endometrial cancer: its association with disease progression and survival

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase is a novel prognostic indicator for endometrial cancer

21 January 2018

1 reference

High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome

21 January 2018

1 reference

Expression of indoleamine 2,3-dioxygenase in metastatic malignant melanoma recruits regulatory T cells to avoid immune detection and affects survival.

21 January 2018

1 reference

Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer

21 January 2018

1 reference

Expression of indoleamine 2,3-dioxygenase in tumor endothelial cells correlates with long-term survival of patients with renal cell carcinoma

21 January 2018

1 reference

High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma.

21 January 2018

1 reference

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase

21 January 2018

1 reference

Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase

21 January 2018

1 reference

A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.

21 January 2018

1 reference

IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-gamma increase in normal pregnancy but decrease in spontaneous abortion

21 January 2018

1 reference

Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight

21 January 2018

1 reference

IDO recruits Tregs in melanoma.

21 January 2018

1 reference

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 January 2018

1 reference

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

21 January 2018

1 reference

Involvement of indoleamine 2,3-dioxygenase in impairing tumor-infiltrating CD8 T-cell functions in esophageal squamous cell carcinoma

21 January 2018

1 reference

Molecular profiling of melanoma and the evolution of patient-specific therapy

21 January 2018

1 reference

Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells

21 January 2018

1 reference

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

Biomarkers for immunostimulatory monoclonal antibodies in combination strategies for melanoma and other tumor types

21 January 2018

1 reference

Skin delivery of short hairpin RNA of indoleamine 2,3 dioxygenase induces antitumor immunity against orthotopic and metastatic liver cancer.

21 January 2018

1 reference

An immune-active tumor microenvironment favors clinical response to ipilimumab

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJD.13100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json

release_7eco4t7f3bbolcqjk4jzdpmi7y

18 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7eco4t7f3bbolcqjk4jzdpmi7y

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24814041%20AND%20SRC:MED&resulttype=core&format=json